Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

NCT04849416 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04849416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04849416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 14, 2021
Completion date
December 29, 2025
Enrollment
87 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic, b-cell, leukemia, lymphoid, lymphoma, b-cell, lymphoma, b-cell, marginal zone, lymphoma, large b-cell, diffuse, lymphoma, mantle-cell, lymphoma, non-hodgkin